NICE recommends Eisai ’s Kisplyx for renal cell carcinoma

Eisai Oncology business group EMEA chairman and CEO Gary Hendler said: “We are delighted that NICE is recommending lenvatinib in combination with everolimus for routine access to adult patients for the treatment of advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.12/14/2017
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news